{"disease":{"id":"smarca4-deficient-tumor","name":"smarca4 deficient tumor"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07121387","title":"A Retrospective Cohort Analysis of SMARCA4-Deficient Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":221,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT05407441","title":"Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":49,"lead_sponsor_name":"Susan Chi, MD","has_results":false},{"nct_id":"NCT07307443","title":"A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":28,"lead_sponsor_name":"Zhijie Wang","has_results":false},{"nct_id":"NCT07200947","title":"A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":28,"lead_sponsor_name":"Zhijie Wang","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}